One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study

Ulrich Schäfer; Christian Butter; Martin Landt; Christian Frerker; Hendrik Treede; Johannes Schirmer; Cornel Koban; Abdelhakim Allali; Tobias Schmidt; Efstratios Charitos; Olga Nikolayevska; Lenard Conradi

doi:10.4244/EIJ-D-20-01241

One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study

Ulrich Schäfer
Christian Butter
Martin Landt
Christian Frerker
Hendrik Treede
Johannes Schirmer
Cornel Koban
Abdelhakim Allali
Tobias Schmidt
Efstratios Charitos
Olga Nikolayevska
Lenard Conradi

Related Research units

Department for Cardiovascular Surgery

Abstract

First-in-human clinical studies and in vitro tests for valve-in-valve (ViV) with the ALLEGRA (New Valve Technology) transcatheter heart valve (THV), as well as the 30-day data of the VIVALL study demonstrated favourable results, even in small surgical aortic bioprostheses123. This paper reports the 12-month outcomes of the VIVALL study.

Bibliographical data

Original language	English
ISSN	1774-024X
DOIs	https://doi.org/10.4244/EIJ-D-20-01241
Publication status	Published - 28.01.2022

PubMed	33775931